Hsbc Holdings PLC Purchases 37,610 Shares of Xencor, Inc. $XNCR

Hsbc Holdings PLC boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 179.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 58,579 shares of the biopharmaceutical company’s stock after purchasing an additional 37,610 shares during the quarter. Hsbc Holdings PLC owned about 0.08% of Xencor worth $717,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Inspire Investing LLC boosted its stake in shares of Xencor by 38.6% in the 1st quarter. Inspire Investing LLC now owns 42,529 shares of the biopharmaceutical company’s stock valued at $513,000 after purchasing an additional 11,853 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of Xencor during the first quarter worth approximately $382,000. OP Asset Management Ltd bought a new stake in shares of Xencor during the first quarter worth approximately $664,000. Diversified Trust Co lifted its holdings in Xencor by 16.7% in the first quarter. Diversified Trust Co now owns 21,528 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 3,086 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new position in Xencor in the fourth quarter valued at approximately $1,677,000.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $21.49 on Friday. Xencor, Inc. has a 52-week low of $6.92 and a 52-week high of $21.76. The stock has a market cap of $1.59 billion, a P/E ratio of -9.38 and a beta of 0.86. The firm has a 50 day moving average price of $14.69 and a 200 day moving average price of $13.10.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The firm had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The company’s revenue for the quarter was down 86.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.66) earnings per share. Analysts predict that Xencor, Inc. will post -3.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on XNCR shares. Wedbush reaffirmed an “outperform” rating and set a $26.00 target price on shares of Xencor in a report on Thursday. Truist Financial dropped their target price on shares of Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. JPMorgan Chase & Co. increased their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Wall Street Zen lowered Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.